Topics

STAT Plus: On the cusp of FDA approval for its NASH drug, Intercept’s CEO talks payers, pruritis, and price

17:48 EST 14 Jan 2020 | STAT

It’s been a long and bumpy road, but Intercept’s NASH drug, called obeticholic acid, is finally on the cusp of a FDA approval. 

Original Article: STAT Plus: On the cusp of FDA approval for its NASH drug, Intercept’s CEO talks payers, pruritis, and price

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: On the cusp of FDA approval for its NASH drug, Intercept’s CEO talks payers, pruritis, and price"

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...